171 related articles for article (PubMed ID: 12796366)
1. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
LoRusso PM; Herbst RS; Rischin D; Ranson M; Calvert H; Raymond E; Kieback D; Kaye S; Gianni L; Harris A; Bjork T; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Feyereislova A; Heyes A; Averbuch SD; Ochs J; Baselga J
Clin Cancer Res; 2003 Jun; 9(6):2040-8. PubMed ID: 12796366
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
4. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
[TBL] [Abstract][Full Text] [Related]
5. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Cella D; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Heyes A; Ochs JS; Wolf MK; Kay AC; Kris MG; Natale RB
J Clin Oncol; 2005 May; 23(13):2946-54. PubMed ID: 15699477
[TBL] [Abstract][Full Text] [Related]
6. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale.
Cella D
Semin Oncol; 2003 Feb; 30(1 Suppl 1):39-48. PubMed ID: 12644983
[TBL] [Abstract][Full Text] [Related]
7. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Herbst RS
Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
Reck M; Gatzemeier U
Respir Med; 2005 Mar; 99(3):298-307. PubMed ID: 15733505
[TBL] [Abstract][Full Text] [Related]
9. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
J Clin Oncol; 2006 Aug; 24(24):3831-7. PubMed ID: 16921034
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Kris MG; Natale RB; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Kelly K; Spiridonidis H; Sandler A; Albain KS; Cella D; Wolf MK; Averbuch SD; Ochs JJ; Kay AC
JAMA; 2003 Oct; 290(16):2149-58. PubMed ID: 14570950
[TBL] [Abstract][Full Text] [Related]
12. Phase I studies of ZD1839 in patients with common solid tumors.
Lorusso PM
Semin Oncol; 2003 Feb; 30(1 Suppl 1):21-9. PubMed ID: 12644981
[TBL] [Abstract][Full Text] [Related]
13. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
[TBL] [Abstract][Full Text] [Related]
14. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res., 9: 2040-2048, 2003.
Patrick-Miller LJ
Clin Cancer Res; 2003 Jun; 9(6):1990-4. PubMed ID: 12796360
[No Abstract] [Full Text] [Related]
16. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
[TBL] [Abstract][Full Text] [Related]
17. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
19. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Leighl NB; Tsao WS; Zawisza DL; Nematollahi M; Shepherd FA
Lung Cancer; 2006 Jan; 51(1):115-21. PubMed ID: 16188343
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
